@article{439df1305fac4e5faceb6d16a02daa45,
title = "Tau-positron emission tomography correlates with neuropathology findings",
abstract = "Introduction: Comparison of tau (flortaucipir) positron emission tomography (FTP-PET) to autopsy is important to demonstrate the relationship of FTP-PET to neuropathologic findings. Methods: Autopsies were performed on 26 participants who had antemortem FTP-PET. FTP-PET standardized uptake value ratios (SUVRs) were compared to autopsy diagnoses and Braak tangle stage. Quantitative tau burden was compared to regional FTP-PET signal. Results: Participants with Braak stages of IV or greater had elevated FTP-PET signal. FTP-PET was elevated in participants with Alzheimer's disease. An FTP-PET SUVR cut point of 1.29 was determined to be optimal. Quantitative measurements of hippocampal and temporal lobe tau burden were highly correlated to FTP-PET signal (rho's from 0.61 to 0.70, P ≤.02). Discussion: Elevated FTP-PET reflects Braak IV or greater neuropathology. Participants with primary age-related tauopathy and hippocampal sclerosis did not show elevated FTP-PET signal. Secondary neuropathologic diagnoses of Alzheimer's disease neuropathologic change can lead to borderline elevated FTP-PET signal.",
keywords = "Alzheimer's disease, Autopsy, Braak tangle stage, PET, Tau, flortaucipir",
author = "Lowe, {Val J.} and Lundt, {Emily S.} and Albertson, {Sabrina M.} and Min, {Hoon Ki} and Ping Fang and Przybelski, {Scott A.} and Senjem, {Matthew L.} and Schwarz, {Christopher G.} and Kejal Kantarci and Bradley Boeve and Jones, {David T.} and Reichard, {R. Ross} and Tranovich, {Jessica F.} and {Hanna Al-Shaikh}, {Fadi S.} and Knopman, {David S.} and Jack, {Clifford R.} and Dickson, {Dennis W.} and Petersen, {Ronald C.} and Murray, {Melissa E.}",
note = "Funding Information: The authors thank the patients and their families who have participated in these prospective clinical and imaging studies, and especially for the generous donation of their brain tissue to help further their knowledge in Alzheimer's disease. The authors would like to acknowledge the continuous commitment and teamwork offered by Mark Jacobsen, Ping Fang, Ariston Librero, Virginia R. Phillips, and Monica Castanedes-Casey. The authors would like to also thank Kris Johnson for assistance in collection of neuropathologic material. The authors would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying the F18-flortaucipir precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. This research was supported by NIH grants, P50 AG016574 , R01 NS89757 , R01 NS089544 , R01 DC10367 , R01 AG011378 , R01 AG041851 , R01 AG034676 , R01 AG054449 , R01 NS097495 , U01 AG006786 , R21 NS094489 , by the Robert Wood Johnson Foundation , The Elsie and Marvin Dekelboum Family Foundation , the Liston Family Foundation , and by the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, the Alexander Family Foundation , the GHR Foundation , Dr. Corinne Schuler and the Mayo Foundation for Medical Education and Research . Funding Information: The authors thank the patients and their families who have participated in these prospective clinical and imaging studies, and especially for the generous donation of their brain tissue to help further their knowledge in Alzheimer's disease. The authors would like to acknowledge the continuous commitment and teamwork offered by Mark Jacobsen, Ping Fang, Ariston Librero, Virginia R. Phillips, and Monica Castanedes-Casey. The authors would like to also thank Kris Johnson for assistance in collection of neuropathologic material. The authors would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying the F18-flortaucipir precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. This research was supported by NIH grants, P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, R01 AG011378, R01 AG041851, R01 AG034676, R01 AG054449, R01 NS097495, U01 AG006786, R21 NS094489, by the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, the Liston Family Foundation, and by the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, the Alexander Family Foundation, the GHR Foundation, Dr. Corinne Schuler and the Mayo Foundation for Medical Education and Research. Dr. Lowe serves as a consultant for Bayer Schering Pharma, Philips Molecular Imaging, Piramal Imaging, and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. Ms. Lundt reports none. Ms. Albertson reports none. Dr. Min reports none. Mr. Przybelski reports none. Mr. Weigand reports none. Mr. Senjem reports none. Dr. Schwarz receives research support from the NIH. Dr. Parisi reports none. Dr. Kantarci serves on the data safety monitoring board for Pfizer Inc. and Jannsen Alzheimer's Immunotherapy; data safety monitoring board for Takeda Global Research & Development Center, Inc. She is funded by the NIH and Minnesota Partnership for Biotechnology and Medical Genomics. Dr. Boeve has served as an investigator for clinical trials sponsored by Axovant and Biogen. He receives royalties from the publication of a book entitled Behavioral Neurology of Dementia (Cambridge Medicine, 2009, 2017). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation. Dr. Jones reports no disclosures. Dr. Reichard reports no disclosures. Mrs. Tranovich reports no disclosures. Mr. Al-Shaikh reports no disclosures. Dr. Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at the University of Southern California; and receives research support from the NIH. Dr. Jack serves on a scientific advisory board for Eli Lilly & Company and on an independent data safety monitoring board for Roche but he receives no personal compensation from any commercial entity. He receives research support from the NIH, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Dickson reports none. Dr. Petersen serves on scientific advisory boards for Roche, Inc.; Merck, Inc.; Biogen, Inc.; Eisai, Inc.; conducted a CME course for GE Healthcare and is on a DSMB for Genentech, Inc.; receives royalties from the publication of Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH/NIA. Dr. Murray receives research support from the NIH/NIA. Publisher Copyright: {\textcopyright} 2019 the Alzheimer's Association",
year = "2020",
month = mar,
day = "1",
doi = "10.1016/j.jalz.2019.09.079",
language = "English (US)",
volume = "16",
pages = "561--571",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",
}